AU2003303339A1 - Lymphotoxin beta receptor agents in combination with chemotherapeutic agents - Google Patents

Lymphotoxin beta receptor agents in combination with chemotherapeutic agents Download PDF

Info

Publication number
AU2003303339A1
AU2003303339A1 AU2003303339A AU2003303339A AU2003303339A1 AU 2003303339 A1 AU2003303339 A1 AU 2003303339A1 AU 2003303339 A AU2003303339 A AU 2003303339A AU 2003303339 A AU2003303339 A AU 2003303339A AU 2003303339 A1 AU2003303339 A1 AU 2003303339A1
Authority
AU
Australia
Prior art keywords
tumor
combination
antibody
dose
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303339A
Other languages
English (en)
Inventor
Alan Gill
Doreen Lepage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of AU2003303339A1 publication Critical patent/AU2003303339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003303339A 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents Abandoned AU2003303339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20
US60/435,185 2002-12-20
PCT/US2003/041243 WO2004058183A2 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
AU2003303339A1 true AU2003303339A1 (en) 2004-07-22

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303339A Abandoned AU2003303339A1 (en) 2002-12-20 2003-12-22 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Country Status (16)

Country Link
US (1) US20060134102A1 (https=)
EP (1) EP1585547A4 (https=)
JP (1) JP2006513225A (https=)
KR (1) KR20050094819A (https=)
CN (1) CN1753692A (https=)
AU (1) AU2003303339A1 (https=)
BR (1) BR0317573A (https=)
CA (1) CA2509495A1 (https=)
EA (1) EA200501019A1 (https=)
IS (1) IS7900A (https=)
MX (1) MXPA05006663A (https=)
NO (1) NO20053529L (https=)
PL (1) PL377611A1 (https=)
RS (1) RS20050481A (https=)
WO (1) WO2004058183A2 (https=)
ZA (1) ZA200505543B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
CA2655411A1 (en) * 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) * 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
ES2776406T3 (es) * 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3807401A1 (en) * 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
WO2020081841A1 (en) 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1900116A (zh) * 1995-01-26 2007-01-24 拜奥根Idec马萨诸塞公司 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
SK55399A3 (en) * 1996-10-25 2000-10-09 Biogen Inc Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Also Published As

Publication number Publication date
MXPA05006663A (es) 2005-09-30
CN1753692A (zh) 2006-03-29
WO2004058183A2 (en) 2004-07-15
BR0317573A (pt) 2005-11-22
EP1585547A4 (en) 2006-10-25
EP1585547A2 (en) 2005-10-19
PL377611A1 (pl) 2006-02-06
NO20053529D0 (no) 2005-07-19
RS20050481A (sr) 2007-08-03
WO2004058183A3 (en) 2004-12-09
EA200501019A1 (ru) 2006-06-30
JP2006513225A (ja) 2006-04-20
KR20050094819A (ko) 2005-09-28
CA2509495A1 (en) 2004-07-15
NO20053529L (no) 2005-09-20
ZA200505543B (en) 2006-12-27
US20060134102A1 (en) 2006-06-22
IS7900A (is) 2005-06-20

Similar Documents

Publication Publication Date Title
AU2003303339A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
RU2748949C2 (ru) Комбинация моноклональных антител агониста ох40 и агониста 4-1вв для лечения рака
AU2016355320B2 (en) Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors
AU2004308749B2 (en) CD40 antibody formulation and methods
US20060104971A1 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
JP2006513225A5 (https=)
JP2020503860A (ja) 免疫応答のコンディショナルアゴニスト
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
CN111166878A (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN116507365A (zh) 抗ox40抗体在治疗肿瘤或癌症中的应用
KR20200072507A (ko) 암 치료를 위한 조합 제품
CN121079314A (zh) 用于组合疗法的方法和组合物
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
CN112439060B (zh) Pd-l1免疫疗法的新用途
WO2024129552A2 (en) Combination therapy of a pd-1 antagonist, a lag3 antagonist and an antibody drug conjugate that binds 191p4d12 protein for treating patients with cancer
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN119546640A (zh) 用于治疗癌症的包含SIRPα融合蛋白和抗CD19抗体的组合疗法
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
HK1172823A (en) Cd40 antibody formulation and methods

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application